TCT-59
Effect of Intracoronary Abciximab and Aspiration Thrombectomy on Microvascular Obstruction in Large Anterior Myocardial Infarction: The INFUSE-AMI MRI Substudy
Akiko Maebaru1, Gary Mintz2, Sorin Brener3, Jan-Henk Dambriki4, Magdi El-Omar5, Anthony Gerstlik6, Martin Fahy7, Roxana Mehran8, C. Michael Gibson9, Gregg Stone10
1Cardiovascular Research Foundation and Columbia University Medical Center, New York, NY, 2TFG, Washington, United States, 3New York Methodist Hospital, Brooklyn, NY, 4Italia klinieki, Zoolle, Netherlands, 5Manchester Heart Centre, Manchester, United Kingdom, 6university hospitals of leicester, Leicester, United Kingdom, 7Cardiovascular Research Foundation, New York, NY, 8Mount Sinai School of Medicine, New York, NY, 9Beth Israel Deacceson Med Ctr - Harvard Medical School, Boston, USA, 10Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY

Background: Microvascular obstruction (MVO) predicts poor outcome in ST-elevation myocardial infarction (STEMI). Whether bolus intracoronary abciximab or manual aspiration thrombectomy will reduce incidence and extent of MVO within the infarction zone in STEMI is unknown.

Methods: INFUSE-AMI was a 2×2 factorial design trial in which patients with proximal or mid left anterior descending (LAD) coronary artery occlusion presenting within 5 hours of symptom onset and receiving bivalirudin anticoagulation were randomized to (1) bolus intracoronary abciximab via the CleanWay RX catheter vs. no abciximab and (2) manual aspiration thrombectomy with the Export catheter vs. no aspiration. A formal substudy included 174 pts who underwent MRI imaging at both 5 and 30 days. MVO was defined as a black area inside the zone of delayed enhancement (i.e. infarction area). This substudy was powered for MVO size as a percentage of total left ventricular (LV) mass, assuming 50% reduction in MVO from 4% (SD 3%) in the control arm to 2% (SD1.5%) with abciximab or thrombectomy.

Results: The extent of MVO was less than predicted in all groups, and was not affected by treatment allocation (Table). Intracoronary abciximab improved left ventricle stroke index at 5 days.

<table>
<thead>
<tr>
<th>Presence of MVO</th>
<th>Abciximab(n = 83)</th>
<th>No Abciximab(n = 83)</th>
<th>p value</th>
<th>Thrombectomy(n = 89)</th>
<th>No Thrombectomy(n = 80)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Presence of MVO</td>
<td>51.6% (47/91)</td>
<td>60.3% (47/78)</td>
<td>0.26</td>
<td>59.6% (47/79)</td>
<td>51.3% (41/80)</td>
<td>0.28</td>
</tr>
</tbody>
</table>

MVO (% of total LV)

| Infarct mass (% of total LV) | 19.6 (12.2) | 23.7 (17.6) | 0.15 | 23.5 (13.3) | 20.2 (12.9) | 0.47 |

LV stroke volume index (cc/m²)

| LV stroke volume index (cc/m²) | 43.3 (35.7) | 39.6 (34.4) | 0.05 | 39.6 (34.3) | 42.6 (35.7) | 0.35 |

LV ejection fraction (%)

| LV ejection fraction (%) | 48.3 (40.3) | 47.6 (41.2) | 0.5  | 48.1 (40.5) | 48.2 (41.2) | 0.86 |

Conclusions: Neither intracoronary abciximab nor thrombectomy affected the frequency and extent of MVO. The low extent of MVO observed with modern first PCI and bivalirudin anticoagulation in patients presenting early after infarct onset is notable.

TCT-60
Comparison Of Manual Aspiration With Rheolytic Thrombectomy In Acute Myocardial Infarction: The Final 6-Month Results Of The SMART Primary PCI Trial
Guido Parodi1, Renato Valentì2, Angela Migliorini3, Nazario Carrabba3, Akiko Maebaru2, Ruhen Vergaro2, Benedetta Bellandi4, Gary Mintz4, David Antoniucci1
1Careggi Hospital, Florence, Italy, 2Cardiovascular Research Foundation, New York, NY, 3CRF, Washington, United States

Background: No data exist regarding the comparison between manual aspiration thrombectomy (MAT) and rheolytic thrombectomy (RT) using the optical coherence tomography (OCT) to assess residual thrombus burden after thrombectomy in acute myocardial infarction (AMI). The SMART trial compared the efficacy of RT and MAT in thrombus removal before direct infarct artery stenting in AMI.

Methods: Single-center, randomized, 2-arm study. The primary end point was residual thrombus burden assessed as number of coronary quadrants containing thrombus by OCT after thrombectomy and before infarct artery stenting. Secondary end points were: 1) angiographic and electrocardiographic signs of reperfusion, 2) 6-month malsexed stent strut rate by follow-up OCT.

Results: Eighty AMI patients (±6 hours from symptom onset) were randomly allocated (1:1) to RT or MAT. There were no significant difference in the baseline clinical and angiographic characteristics between the 2 study groups. All but 1 patient had residual thrombus after MAT or RT. The number of coronary quadrants containing thrombus were 53 (31.83) in the RT arm and 65 (33.11) in MAT arm, respectively (p = 0.083); while maximal thrombus area was 1.7 (0.7-2.6) and 2.0 (1.1-3.5), respectively (p = 0.092). Large residual thrombus defined as the number of quadrants containing thrombus > the median value was more frequent in the MAT arm than in the RT arm (60% and 37%, p = 0.039). Patients treated with RT were more likely to have a post-thrombectomy coronary TIMI grade 3 flow (87% vs 57%, p = 0.003), and a lower TIMI thrombus grade 1.6 ± 0.9 vs 2.4 ± 1.2, (p = 0.001) as compared to MAT. After infarct artery stenting patients randomized to RT were more likely to have a final TIMI grade 3 flow (95% vs 80%, p = 0.043) and TIMI grade 3 blush (72% vs 50%, p = 0.039), and early ST-segment elevation resolution (92% vs 77%, p = 0.060), as compared to MAT. The relationship between baseline residual thrombus burden by OCT and 6-month stent malsexed rate will be presented at the meeting.

Conclusions: MAT or RT allow only incomplete removal of thrombus in the setting of AMI. RT as compared to MAT is more effective in thrombus removal and is associated with a better myocardial reperfusion.

TCT-61
Infarct Size-Determined Uptake of CD34+ Cells in the Peri-Infarct Zone and Left Ventricular Remodeling: Insights from Integration of Labeled Cells Uptake SPECT Visualization with Sequential Cardiac MRI
Piotr Musialek1, Lukasz Tekielski2, Magdalena Stokiewicz2, Tomasz Mitzalski-Jamka3, Wojciech Szoł3, Wojciech Mazur4, R. Pawel Bany5, Marcin Majka6, Danuta Jarocha2, Zbigniew Walter2, Dean Kereiakes6, Piotr Podolec7, Wojciech Wojakowski8
1Jagiellonian University Institute of Cardiology, John Paul II Hospital, Krakow, Poland, 2Ludwik Guttmann Heart Institute, Krakow, Poland, 3Jagiellonian University Institute of Cardiology, Krakow, Poland, 4John Paul II Hospital, Krakow, Poland, 5The Christ Hospital Heart and Vascular Center, Cincinnati, OH, 6The Christ Hospital Heart & Vascular Center, Cincinnati, USA, 7Medical University of Silesia, Katowice, Poland

Background: Infarct size (IS) is a well-established determinant of adverse LV remodeling. Experimental evidence indicates that attenuation of LV remodeling is critically dependent on salvage of apoptosis-prone myocytes in the peri-infarct zone.

Methods: Thirty-one subjects (age 36-69 years) with pPCI-treated anterior STEMI, peak TnI (183±36ng/dL) (median [range] and sustained LVEF<45% were included. Day 10 [7-12], 4.3±6.0% (0.7-9.9±10.6)90min-extravasation-labeled CD34+ cells were administered transcoronary (LAD). Gadolinium late-enhanced total infarct mass (IS, cMRI) was 57 (11-112)g. One hour after administration, 1.7-9.9% labeled cells activity localized in myocardium (whole-body 8-scan). Results: Image fusion of labeled cells SPECT with LV perfusion SPECT or cMRI infarct images predicted peri-infarct zone cell uptake. Labeled cells early engraftment correlated with salvage of apoptosis-prone myocytes in the peri-infarct zone. Early ST-segment elevation resolution (92% vs 77%, p = 0.003). IS was more frequent in the MAT arm than in the RT arm (60% and 37%, p = 0.039). Patients treated with RT were more likely to have a post-thrombectomy coronary TIMI grade 3 flow (87% vs 57%, p = 0.003), and a lower TIMI thrombus grade 1.6 ± 0.9 vs 2.4 ± 1.2, (p = 0.001) as compared to MAT. After infarct artery stenting patients randomized to RT were more likely to have a final TIMI grade 3 flow (95% vs 80%, p = 0.043) and TIMI grade 3 blush (72% vs 50%, p = 0.039), and early ST-segment elevation resolution (92% vs 77%, p = 0.060), as compared to MAT. The relationship between baseline residual thrombus burden by OCT and 6-month stent malsexed rate will be presented at the meeting.

Conclusions: MAT or RT allow only incomplete removal of thrombus in the setting of AMI. RT as compared to MAT is more effective in thrombus removal and is associated with a better myocardial reperfusion.

TUESDAY, OCTOBER 23, 10:30 AM–12:30 PM